A study reported by I-Fen Chen (128) demonstrated that the expression of AIM2 restrained breast cancer tumorigenicity and proliferation in vivo and vitro. Furthermore, combined with innate immune agonists, high intensity focused ultrasound (HIFU) in conjunction with innate immune stimulators could upregulate multiple innate immune receptors including AIM2 in mice with multi-focal breast cancer, which enhanced response to innate immune agonists (129). This evidence concerns the gene AIM2 and breast carcinoma.